Pharyngitis: Difference between revisions

(Move calculators to own section with header (visible in TOC), expanded, before External Links)
(Strip excess bold)
 
Line 92: Line 92:


===Key Evaluation Principles===
===Key Evaluation Principles===
*Do '''not''' test patients with clear viral features ([[cough]], [[rhinorrhea]], hoarseness, oral ulcers, [[conjunctivitis]]) — treat supportively<ref name="idsa2012"/><ref name="idsa2025"/>
*Do not test patients with clear viral features ([[cough]], [[rhinorrhea]], hoarseness, oral ulcers, [[conjunctivitis]]) — treat supportively<ref name="idsa2012"/><ref name="idsa2025"/>
*Do '''not''' routinely test children <3 years of age (both GAS and [[acute rheumatic fever]] are rare), unless risk factors (e.g., sibling with GAS)<ref name="idsa2012"/>
*Do not routinely test children <3 years of age (both GAS and [[acute rheumatic fever]] are rare), unless risk factors (e.g., sibling with GAS)<ref name="idsa2012"/>
*The 2025 IDSA guideline update recommends using a standardized clinical scoring system (e.g., Modified Centor/McIsaac) to identify low-risk patients who do not need testing<ref name="idsa2025"/>
*The 2025 IDSA guideline update recommends using a standardized clinical scoring system (e.g., Modified Centor/McIsaac) to identify low-risk patients who do not need testing<ref name="idsa2025"/>
*For those meeting testing criteria: use Rapid Antigen Detection Test (RADT)
*For those meeting testing criteria: use Rapid Antigen Detection Test (RADT)
Line 101: Line 101:
*Centor/McIsaac score of 0-1: do not test, treat symptomatically
*Centor/McIsaac score of 0-1: do not test, treat symptomatically
*Centor/McIsaac score of ≥2: test with RADT (± backup culture in children)
*Centor/McIsaac score of ≥2: test with RADT (± backup culture in children)
*Do '''not''' test asymptomatic contacts routinely<ref name="idsa2012"/>
*Do not test asymptomatic contacts routinely<ref name="idsa2012"/>
*Do '''not''' perform test of cure after treatment unless history of [[acute rheumatic fever]] or recurrent GAS complications<ref name="idsa2012"/>
*Do not perform test of cure after treatment unless history of [[acute rheumatic fever]] or recurrent GAS complications<ref name="idsa2012"/>


===Additional Testing to Consider (When Clinically Indicated)===
===Additional Testing to Consider (When Clinically Indicated)===
Line 112: Line 112:
==Management==
==Management==
===Symptomatic Treatment===
===Symptomatic Treatment===
*'''Analgesics/antipyretics''' are the foundation of treatment for ALL pharyngitis (viral and bacterial)
*Analgesics/antipyretics are the foundation of treatment for ALL pharyngitis (viral and bacterial)
**[[Ibuprofen]] 400-600mg PO q6h PRN (adults); 10 mg/kg PO q6h PRN (pediatric)
**[[Ibuprofen]] 400-600mg PO q6h PRN (adults); 10 mg/kg PO q6h PRN (pediatric)
**[[Acetaminophen]] 1000mg PO q6h PRN (adults); 15 mg/kg PO q4-6h PRN (pediatric)
**[[Acetaminophen]] 1000mg PO q6h PRN (adults); 15 mg/kg PO q4-6h PRN (pediatric)
**Ibuprofen may be slightly more effective for throat pain than acetaminophen<ref name="mahp"/>
**Ibuprofen may be slightly more effective for throat pain than acetaminophen<ref name="mahp"/>
**Avoid [[aspirin]] in children ([[Reye syndrome]])
**Avoid [[aspirin]] in children ([[Reye syndrome]])
*'''Topical therapies:'''
*Topical therapies:
**Salt water gargle
**Salt water gargle
**Viscous [[lidocaine]] (adults) — use with caution due to aspiration risk
**Viscous [[lidocaine]] (adults) — use with caution due to aspiration risk
**Consider "magic mouthwash" ([[diphenhydramine]]/[[lidocaine]]/antacid mixture)
**Consider "magic mouthwash" ([[diphenhydramine]]/[[lidocaine]]/antacid mixture)
*'''Hydration:''' encourage oral fluids, soft diet; assess ability to tolerate PO before discharge
*Hydration: encourage oral fluids, soft diet; assess ability to tolerate PO before discharge


===[[Antibiotics]]===
===[[Antibiotics]]===
Line 128: Line 128:
*Treatment is indicated for laboratory-confirmed GAS pharyngitis (RADT or culture positive)<ref name="idsa2012"/>
*Treatment is indicated for laboratory-confirmed GAS pharyngitis (RADT or culture positive)<ref name="idsa2012"/>
*'''Do not''' treat empirically based on clinical features alone in most cases<ref name="idsa2025"/>
*'''Do not''' treat empirically based on clinical features alone in most cases<ref name="idsa2025"/>
*'''Goal:''' prevent [[acute rheumatic fever]], reduce suppurative complications, improve symptoms, decrease transmission
*Goal: prevent [[acute rheumatic fever]], reduce suppurative complications, improve symptoms, decrease transmission
*'''Key point:''' antibiotics shorten symptom duration by approximately 1-2 days when started early<ref name="spinks">Spinks A, Glasziou PP, Del Mar CB. Antibiotics for treatment of sore throat in children and adults. Cochrane Database Syst Rev. 2021;12:CD000023.</ref>
*Key point: antibiotics shorten symptom duration by approximately 1-2 days when started early<ref name="spinks">Spinks A, Glasziou PP, Del Mar CB. Antibiotics for treatment of sore throat in children and adults. Cochrane Database Syst Rev. 2021;12:CD000023.</ref>


===[[Steroids]]===
===[[Steroids]]===
Line 141: Line 141:
*Discharge home with symptomatic treatment ± antibiotics
*Discharge home with symptomatic treatment ± antibiotics
*Patient can return to work/school after ≥24 hours of antibiotic therapy and clinical improvement (for confirmed GAS)<ref name="cdc">CDC. Clinical Guidance for Group A Streptococcal Pharyngitis. Centers for Disease Control and Prevention. Updated November 2025. https://www.cdc.gov/group-a-strep/hcp/clinical-guidance/strep-throat.html</ref>
*Patient can return to work/school after ≥24 hours of antibiotic therapy and clinical improvement (for confirmed GAS)<ref name="cdc">CDC. Clinical Guidance for Group A Streptococcal Pharyngitis. Centers for Disease Control and Prevention. Updated November 2025. https://www.cdc.gov/group-a-strep/hcp/clinical-guidance/strep-throat.html</ref>
*'''Return precautions:'''
*Return precautions:
**Unable to tolerate oral fluids
**Unable to tolerate oral fluids
**Worsening sore throat or new difficulty swallowing despite treatment
**Worsening sore throat or new difficulty swallowing despite treatment

Latest revision as of 09:32, 22 March 2026

Background

Anatomy of the posterior pharynx.

Streptococcal pharyngitis

  • Accounts for 5-15% of pharyngitis in adults and 15-30% in children[4]
  • Peak incidence in ages 5-15 years
  • Rare in children <3 years of age (typically presents as "streptococcosis" with rhinitis/low-grade fever rather than classic pharyngitis)
  • Seasonal: winter and early spring
  • Treatment can be delayed for up to 9 days from symptom onset and still prevent acute rheumatic fever[5]

Clinical Features

Generalized erythema of the pharynx, consistent with pharyngitis.
Culture positive strep pharyngitis with typical tonsillar exudate

General

Features Favoring Bacterial (GAS) Etiology

  • Sudden onset sore throat
  • Fever ≥38.3°C (101°F)
  • Tonsillar exudate
  • Tender anterior cervical lymphadenopathy
  • Absence of cough, rhinorrhea, conjunctivitis, hoarseness, or oral ulcers[5]

Features Favoring Viral Etiology

Classic Clues for Specific Diagnoses

Modified Centor Criteria[8]

One point is given for each of the criteria:[8]

  1. Absence of a cough
  2. Swollen and tender cervical lymph nodes
  3. Temperature >38.0 °C (100.4 °F)
  4. Tonsillar exudate or swelling
  5. Age less than 15^
    • Subtract a point if age >44
Modified Centor score
Points Probability of Streptococcal pharyngitis
1 or fewer <10%
2 11–17%
3 28–35%
4 or 5 52%

ED Red Flags

Complications

Suppurative

Nonsuppurative

Differential Diagnosis

Acute Sore Throat

Bacterial infections


Viral infections


Noninfectious


Other

Oral rashes and lesions

Evaluation

Rapid Antigen Detection Test Algorithm for Acute Pharyngitis[10]

Category Testing and Treatment
Clinical features strongly suggesting viral etiology (eg. cough, rhinorrhea, hoarseness, oral ulcers)
  • None
<3 years old
  • None because immature immune system not mature enough to develop anti-streptolysin O (ASO) antibodies and acute rheumatic fever[11].
    • Unless they have a special risk factor (e.g. older sibling with GAS infection)
CENTOR = 1
  • None
None of the above with CENTOR ≥2
  • Send rapid antigen detection test
    • Positive = treat
    • Negative
      • Children and adolescents
        • Send back up throat culture (treat later, if positive)
      • Adults
        • None (no need for back up throat culture)

Diagnostic testing or empiric treatment of asymptomatic household contacts of patients with acute streptococcal pharyngitis is not routinely recommended

Key Evaluation Principles

  • Do not test patients with clear viral features (cough, rhinorrhea, hoarseness, oral ulcers, conjunctivitis) — treat supportively[5][4]
  • Do not routinely test children <3 years of age (both GAS and acute rheumatic fever are rare), unless risk factors (e.g., sibling with GAS)[5]
  • The 2025 IDSA guideline update recommends using a standardized clinical scoring system (e.g., Modified Centor/McIsaac) to identify low-risk patients who do not need testing[4]
  • For those meeting testing criteria: use Rapid Antigen Detection Test (RADT)
    • RADT sensitivity 70-90%, specificity >95%
    • In children/adolescents: a negative RADT should be backed up with a throat culture (higher false-negative rate)[5]
    • In adults: backup throat culture generally not required (lower incidence and lower risk of acute rheumatic fever)[5]
  • Centor/McIsaac score of 0-1: do not test, treat symptomatically
  • Centor/McIsaac score of ≥2: test with RADT (± backup culture in children)
  • Do not test asymptomatic contacts routinely[5]
  • Do not perform test of cure after treatment unless history of acute rheumatic fever or recurrent GAS complications[5]

Additional Testing to Consider (When Clinically Indicated)

Management

Symptomatic Treatment

  • Analgesics/antipyretics are the foundation of treatment for ALL pharyngitis (viral and bacterial)
    • Ibuprofen 400-600mg PO q6h PRN (adults); 10 mg/kg PO q6h PRN (pediatric)
    • Acetaminophen 1000mg PO q6h PRN (adults); 15 mg/kg PO q4-6h PRN (pediatric)
    • Ibuprofen may be slightly more effective for throat pain than acetaminophen[2]
    • Avoid aspirin in children (Reye syndrome)
  • Topical therapies:
  • Hydration: encourage oral fluids, soft diet; assess ability to tolerate PO before discharge

Antibiotics

Treatment can be delayed for up to 9 days and still prevent major sequelae

Penicillin Options:

Penicillin allergic (mild):

Penicillin allergic (anaphylaxis):[13]

  • Clindamycin 7 mg/kg/dose TID (maximum = 300 mg/dose) x 10 days[19]
  • Azithromycin 12 mg/kg PO once (maximum = 500 mg), then 6 mg/kg (max=250 mg) once daily for the next 4 days[20]
  • Clarithromycin 7.5 mg/kg/dose PO BID (maximum = 250 mg/dose) x 10 days[21]


Pediatric Dosing:

  • Amoxicillin 50mg/kg PO once daily x 10 days (max 1000mg)
  • Penicillin V <27kg: 250mg PO BID-TID x 10 days; >27kg: 500mg PO BID-TID x 10 days
  • Penicillin G Benzathine <27kg: 600,000 units IM x 1; >27kg: 1.2 million units IM x 1
  • PCN allergy (mild): Cephalexin 20mg/kg PO BID x 10 days (max 500mg/dose)
  • PCN allergy (mild): Cefadroxil 30mg/kg PO daily x 10 days (max 1g)
  • PCN allergy (severe): Azithromycin 12mg/kg PO day 1 (max 500mg), then 6mg/kg daily x 4 days (max 250mg)
  • PCN allergy (severe): Clindamycin 7mg/kg/dose PO TID x 10 days (max 300mg/dose)
  • PCN allergy (severe): Clarithromycin 7.5mg/kg PO BID x 10 days (max 250mg/dose)
  • Treatment is indicated for laboratory-confirmed GAS pharyngitis (RADT or culture positive)[5]
  • Do not treat empirically based on clinical features alone in most cases[4]
  • Goal: prevent acute rheumatic fever, reduce suppurative complications, improve symptoms, decrease transmission
  • Key point: antibiotics shorten symptom duration by approximately 1-2 days when started early[24]

Steroids

  • In adults consider single dose of dexamethasone 0.6mg/kg PO (Max = 10mg)[25]
    • Reduces pain severity and time to onset of pain relief (~4-12 hours faster resolution)
  • In children consider single dose of dexamethasone 0.6mg/kg PO (Max = 10mg)[26]
  • Note: The 2012 IDSA guideline did not recommend routine adjunctive corticosteroids; however, emergency medicine literature supports their use for pain relief[5]

Disposition

Discharge (Majority of Patients)

  • Discharge home with symptomatic treatment ± antibiotics
  • Patient can return to work/school after ≥24 hours of antibiotic therapy and clinical improvement (for confirmed GAS)[27]
  • Return precautions:
    • Unable to tolerate oral fluids
    • Worsening sore throat or new difficulty swallowing despite treatment
    • Difficulty breathing or changes in voice
    • Persistent or worsening fever after 48 hours of antibiotics
    • New unilateral neck swelling or stiffness

Consider Admission

  • Inability to tolerate oral fluids (especially in children) → IV hydration
  • Concern for airway compromise
  • Sepsis or toxic appearance
  • Suspected deep neck space infection, Lemierre's syndrome, or other suppurative complication requiring IV antibiotics and imaging

ED Pearls

  • Most sore throats are viral — focus on symptom management and avoid unnecessary antibiotics
  • Centor Criteria help identify who does NOT need testing (score 0-1), not who has strep
  • Exudate ≠ bacterial; viral pharyngitis frequently causes exudates
  • Treatment for GAS can be safely delayed up to 9 days and still prevent acute rheumatic fever — you do not need to prescribe empiric antibiotics from the ED without testing
  • Think about Fusobacterium necrophorum and Lemierre's syndrome in any adolescent or young adult with a prolonged, severe, or worsening sore throat, especially with lateral neck pain/swelling or signs of sepsis[3]
  • Post-streptococcal glomerulonephritis is NOT prevented by antibiotic treatment (unlike acute rheumatic fever)
  • Infectious mononucleosis + amoxicillin/ampicillin = maculopapular rash (present in up to 70-100% of cases)
  • Consider acute HIV in any patient with a mononucleosis-like illness and negative Monospot
  • Always assess for ability to tolerate PO fluids before discharging pharyngitis patients, particularly young children

Calculators

Centor/McIsaac Score

Modified Centor (McIsaac) Score
Criteria No (0) Yes (+1)
Tonsillar exudates or swelling 0 1
Tender/swollen anterior cervical lymph nodes 0 1
Temperature >38°C (100.4°F) 0 1
Absence of cough 0 1
Age modifier (McIsaac modification)
Age 3–14 years 0 1 (+1)
Age 15–44 years (0 points — default)
Age ≥45 years 0 -1 (−1)
Modified Centor Score 0   / 5
Interpretation & Management
≤0 ~1–2.5% strep probability — No testing or antibiotics needed.
1 ~5–10% strep probability — No testing or antibiotics needed (optional rapid strep if high clinical suspicion).
2–3 ~11–35% strep probability — Rapid strep testing recommended; treat if positive.
4–5 ~51–53% strep probability — Consider empiric antibiotics or rapid strep test.
References
  • Centor RM et al. The diagnosis of strep throat in adults. Med Decis Making. 1981;1:239-246. PMID 6763125.
  • McIsaac WJ et al. A clinical score to reduce unnecessary antibiotic use. CMAJ. 1998;158:75-83. PMID 9475915.

See Also

References

  1. Hildreth AF, Takhar S, Clark MA, Hatten B. Evidence-Based Evaluation And Management Of Patients With Pharyngitis In The Emergency Department. Emerg Med Pract. 2015;17(9):1-16.
  2. 2.0 2.1 Michigan Quality Improvement Consortium. Acute Pharyngitis in Children (3 years and older), Adolescents and Adults Guideline. 2025.
  3. 3.0 3.1 Centor RM. Expand the pharyngitis paradigm for adolescents and young adults. Ann Intern Med. 2009;151(11):812-815.
  4. 4.0 4.1 4.2 4.3 Barshak MB, Dien Bard J, Linder J, et al. 2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America: Diagnosis of Group A Streptococcal Pharyngitis. Clin Infect Dis. 2025.
  5. 5.0 5.1 5.2 5.3 5.4 5.5 5.6 5.7 5.8 5.9 Shulman ST, Bisno AL, Clegg HW, et al. Clinical Practice Guideline for the Diagnosis and Management of Group A Streptococcal Pharyngitis: 2012 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2012;55(10):e86-102.
  6. Fine AM, Nizet V, Mandl KD. Large-scale validation of the Centor and McIsaac scores to predict group A streptococcal pharyngitis. Arch Intern Med. 2012;172(11):847-852.
  7. 7.0 7.1 Kuppalli K, Livorsi D, Talati NJ, Osborn M. Lemierre's syndrome due to Fusobacterium necrophorum. Lancet Infect Dis. 2012;12(10):808-815.
  8. 8.0 8.1 Choby BA (March 2009). "Diagnosis and treatment of streptococcal pharyngitis". Am Fam Physician 79 (5): 383–90. PMID 19275067.
  9. Melio, Frantz, and Laurel Berge. “Upper Respiratory Tract Infection.” In Rosen’s Emergency Medicine., 8th ed. Vol. 1, n.d.
  10. Shulman, et al. Clinical Practice Guideline for the Diagnosis and Management of Group A Streptococcal Pharyngitis: 2012 Update by the Infectious Diseases Society of America. Clinical Infectious Diseases 2012;55(10):1279–82
  11. David Cisewski An Understated Myth? Strep Throat & Rheumatic Fever
  12. Beyea JA, et al. Pharyngitis: Approach to diagnosis and treatment. Can Fam Physician. 2020;66(4):251-257.
  13. 13.0 13.1 13.2 Shulman, et al. Clinical Practice Guideline for the Diagnosis and Management of Group A Streptococcal Pharyngitis: 2012 Update by the Infectious Diseases Society of America. Clinical Infectious Diseases 2012;55(10):1279–82
  14. CDC Website, accessed 2026-28-01. https://www.cdc.gov/group-a-strep/hcp/clinical-guidance/strep-throat.html
  15. CDC Website, accessed 2026-28-01. https://www.cdc.gov/group-a-strep/hcp/clinical-guidance/strep-throat.html
  16. CDC Website, accessed 2026-28-01. https://www.cdc.gov/group-a-strep/hcp/clinical-guidance/strep-throat.html
  17. CDC Website, accessed 2026-28-01. https://www.cdc.gov/group-a-strep/hcp/clinical-guidance/strep-throat.html
  18. CDC Website, accessed 2026-28-01. https://www.cdc.gov/group-a-strep/hcp/clinical-guidance/strep-throat.html
  19. CDC Website, accessed 2026-28-01. https://www.cdc.gov/group-a-strep/hcp/clinical-guidance/strep-throat.html
  20. CDC Website, accessed 2026-28-01. https://www.cdc.gov/group-a-strep/hcp/clinical-guidance/strep-throat.html
  21. CDC Website, accessed 2026-28-01. https://www.cdc.gov/group-a-strep/hcp/clinical-guidance/strep-throat.html
  22. CDC Website, accessed 2026-28-01. https://www.cdc.gov/group-a-strep/hcp/clinical-guidance/strep-throat.html
  23. CDC Website, accessed 2026-28-01. https://www.cdc.gov/group-a-strep/hcp/clinical-guidance/strep-throat.html
  24. Spinks A, Glasziou PP, Del Mar CB. Antibiotics for treatment of sore throat in children and adults. Cochrane Database Syst Rev. 2021;12:CD000023.
  25. EBQ:TOAST Trial
  26. Olympia RP. The Effectiveness of Oral Dexamethasone in the Treatment of Moderate to Severe Pharyngitis in Children and Young Adults. Acad Emerg Med. 2003;10(5). doi:10.1197/aemj.10.5.434-a
  27. CDC. Clinical Guidance for Group A Streptococcal Pharyngitis. Centers for Disease Control and Prevention. Updated November 2025. https://www.cdc.gov/group-a-strep/hcp/clinical-guidance/strep-throat.html